CEE’s leading pharma Richter Gedeon has acquired a "significant stake" and entered into a business development partnership with Granata Bio, a US-based company specialising in reproductive health, CEO Gabor Orban announced at a press conference after the release of the Q1 earnings report on May 13.

As a result of the acquisition, Richter will gain a seat on Granata Bio's board, he added.

The move reflects Richter’s broader ambition to strengthen its Women’s Healthcare (WHC) division and deepen its commercial and strategic presence in the United States, the world’s largest pharmaceutical market.

Granata Bio was described as an "ideal partner" in helping Richter reach these goals, offering strong ties to key opinion leaders and effective market access across the US.

The collaboration also includes a binding agreement to jointly develop Bemfola, Richter’s recombinant follicle-stimulating hormone product, for the US market. Additionally, the parties signed a royalty purchase agreement for Granata Bio’s human menopausal gonadotropin (hMG), ensuring future royalty revenues for Richter.

Infertility treatment is a core therapeutic focus for Richter. The company’s latest move signals a clear commitment to growing its WHC portfolio and capitalising on the expanding demand for fertility solutions in the United States.

Fielding a question, Orban noted that the impact of US tariffs on Richter will likely be limited.

After the Q1 report, Richter has confirmed its full-year growth of 10% in revenue and operating profit. The BSE-listed company booked a HUF68.5bn (€170mn) in clean EBIT, up 7% year on year on HUF224bn, up 10%, in line with projections.